Dear Editor, I read the recent publication by Sasaki et al. with great interest. Sasaki et al. concluded that "Patients who underwent surgical resection were not evenly divided across UICC-TNM staging categories in comparison to JSBS staging. Stratification of survival ability was better when using the JSBS staging in comparison to the UICC-TNM system [1] ." I agree that JSBS might be a good classification system. However, there are still some remaining questions. In general, there are many other systems for the classification of cholangiocarcinoma including the American Joint Committee on Cancer, Bismuth-Corlette, and the modified Memorial Sloan-Kettering Cancer Center classification [2, 3] . Additional comparative assessment of those systems will give useful data on making a decision in using the best classification system. Also, the cost and effectiveness of each system, which might be different due to system-specific criteria, should be focused and further cost-effectiveness analysis should be done.
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